Terms: = Liver cancer AND CD52, CDW52, EDDM5
10 results:
1. Novel miRNA-based drug CD5-2 reduces liver tumor growth in diethylnitrosamine-treated mice by normalizing tumor vasculature and altering immune infiltrate.
Liu K; Chen J; Zhao Y; Boland J; Ting KK; Lockwood G; McKenzie C; Kench J; Vadas MA; Gamble JR; McCaughan GW
Front Immunol; 2023; 14():1245708. PubMed ID: 37795103
[TBL] [Abstract] [Full Text] [Related]
2. The VE-Cadherin/β-catenin signalling axis regulates immune cell infiltration into tumours.
Zhao Y; Li J; Ting KK; Chen J; Coleman P; Liu K; Wan L; Moller T; Vadas MA; Gamble JR
Cancer Lett; 2021 Jan; 496():1-15. PubMed ID: 32991950
[TBL] [Abstract] [Full Text] [Related]
3. Targeting miR-27a/VE-cadherin interactions rescues cerebral cavernous malformations in mice.
Li J; Zhao Y; Choi J; Ting KK; Coleman P; Chen J; Cogger VC; Wan L; Shi Z; Moller T; Zheng X; Vadas MA; Gamble JR
PLoS Biol; 2020 Jun; 18(6):e3000734. PubMed ID: 32502201
[TBL] [Abstract] [Full Text] [Related]
4. Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.
Zhao Y; Ting KK; Li J; Cogger VC; Chen J; Johansson-Percival A; Ngiow SF; Holst J; Grau G; Goel S; Muller T; Dejana E; McCaughan G; Smyth MJ; Ganss R; Vadas MA; Gamble JR
Cancer Res; 2017 Aug; 77(16):4434-4447. PubMed ID: 28655790
[TBL] [Abstract] [Full Text] [Related]
5. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.
Leskov I; Pallasch CP; Drake A; Iliopoulou BP; Souza A; Shen CH; Schweighofer CD; Abruzzo L; Frenzel LP; Wendtner CM; Hemann MT; Chen J
Oncogene; 2013 Feb; 32(8):1066-1072. PubMed ID: 22484426
[TBL] [Abstract] [Full Text] [Related]
6. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis.
Strout MP; Seropian S; Berliner N
Nat Rev Clin Oncol; 2010 Jul; 7(7):415-20. PubMed ID: 20404855
[TBL] [Abstract] [Full Text] [Related]
7. Extensive flow cytometric characterization of plasmacytoid dendritic cell leukemia cells.
Gopcsa L; Banyai A; Jakab K; Kormos L; Tamaska J; Matolcsy A; Gogolak P; Rajnavolgyi E; Paloczi K
Eur J Haematol; 2005 Oct; 75(4):346-51. PubMed ID: 16146542
[TBL] [Abstract] [Full Text] [Related]
8. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-cd52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
Chanan-Khan A; Islam T; Alam A; Miller KC; Gibbs J; Barcos M; Czuczman MS; Paplham P; Hahn T; McCarthy P
Leuk Lymphoma; 2004 Aug; 45(8):1673-5. PubMed ID: 15370223
[TBL] [Abstract] [Full Text] [Related]
9. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Keating MJ; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
J Clin Oncol; 2002 Jan; 20(1):205-13. PubMed ID: 11773171
[TBL] [Abstract] [Full Text] [Related]
10. Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H.
Hutchins JT; Kull FC; Bynum J; Knick VC; Thurmond LM; Ray P
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):11980-4. PubMed ID: 8618827
[TBL] [Abstract] [Full Text] [Related]
